Table II. Phosphorylation sites of the final phosphosignature.

Uniprot identification code	Gene/protein name	Site	Modified sequencea	Average rankb	Median differencec	Rank ≤12d	SV weighte
P16144-2	ITGB4	Ser1448	DYSTLTSVSpSHDSR	2.716	1.544	18	−0.386
	Integrin β4
Q9UQB8-5	BAIAP2	Ser509	pSMSSADVEVARF	3.611	1.197	18	−0.311
	Brain-specific angiogenesis inhibitor 1-associated protein 2
P16144-2	ITGB4	Ser1387	MDFAFPGSTNpSLHR	4.337	0.992	19	−0.155
	Integrin β4
P16144-2	ITGB4	Thr1385	MDFAFPGSpTNSLHR	5.716	0.937	18	−0.275
	Integrin β4
P16144-2	ITGB4	Ser1069	LLELQEVDpSLLRGR	7.937	1.236	13	−0.076
	Integrin β4
A8K556	GPCR5A	Ser345	AHAWPpSPYKDYEVK	9.632	0.872	16	−0.174
	Retinoic acid-induced protein 3
Q14573	ITPR3	Ser916	pSIQGVGHMMSTMVLSR	14.168	0.782	8	−0.205
	Inositol 1,4,5-trisphosphate receptor type 3
Q9C0C2	TNKS1BP1	Ser429	RFpSEGVLQSPSQDQEK	15.032	0.968	1	−0.159
	182-kDa tankyrase-1-binding protein
Q6ZSZ5	ARHGEF18	Ser1101	pSLSPILPGR	16.874	0.419	0	−0.188
	Rho guanine nucleotide
Q8WUF5	IASPP	Ser102	SEpSAPTLHPYSPLSPK	17.516	0.528	7	−0.145
	RelA-associated inhibitor exchange factor 18
Q676U5	APG16L	Ser269	RLpSQPAGGLLDSITNIFGR	18.19	0.725	13	−0.24
	Autophagy-related protein 16–1
O43399-2	TPD52L2	Ser141	KLGDMRNpSATFK	18.274	0.563	8	−0.155
	Tumor protein D54

^a Sequence of the peptide on which the phosphosite was detected; p indicates that the subsequent amino acid was phosphorylated.

^b The average rank of the feature across all cross-validation steps.

^c Median difference of log10 ratios between sensitive and resistant classes.

^d The number of times the feature was among the 12 best across all CV steps.

^e The importance of the feature in the SVM predictor (the larger the absolute weight, the more important).